Science Explorer Back to mapMap

Most cited papers from Innovation Pharmaceuticals (United States)

Innovation Pharmaceuticals (United States)

What are the most cited papers from Innovation Pharmaceuticals (United States)?

The most cited paper from Innovation Pharmaceuticals (United States) is "Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture" (Allison Bakovic, Kenneth H. Risner, Nishank Bhalla et al., 2021), with 54 citations. Next come "Brilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2" (15) and "Brilacidin, a Non-Peptide Defensin-Mimetic Molecule, Inhibits SARS-CoV-2 Infection by Blocking Viral Entry." (13).

Showing 11 of 11 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture Allison Bakovic, Kenneth H. Risner, Nishank Bhalla et al. · Viruses Open access 9 Feb 2021 54
2 Brilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2 Allison Bakovic, Kenneth H. Risner, Nishank Bhalla et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access 30 Oct 2020 15
3 Brilacidin, a Non-Peptide Defensin-Mimetic Molecule, Inhibits SARS-CoV-2 Infection by Blocking Viral Entry. Chuan Xu, Annie Wang, William J. Honnen et al. · PubMed Open access Apr 2022 13
4 Application of Artificial Intelligence/Machine Vision & Learning for the Development of a Live Single-cell Phenotypic Biomarker Test to Predict Prostate Cancer Tumor Aggressiveness. Jonathan S. Varsanik, Michael S. Manak, Matthew J. Whitfield et al. · PubMed Open access 2020 2
5 Enhancing the explainability of the default probability model using the logic learning machine: A comparison between native “white boxes” machine learning techniques Pier Giuseppe Giribone, Serena Berretta, Michelangelo Fusaro et al. · International Journal of Financial Engineering 27 Jun 2025 1
6 Trusted SMEs for Sustainable Growth of Europeans Economical Backbone to Strengthen the Digital Sovereignty: The KDT Resilient Trust Project Hassan Aboushady, Noémie Béringuier-Boher, Kelly A. Burke et al. Conference paper 28 Aug 2024 1
7 Association of a history of acute kidney injury with major adverse cardiovascular events in chronic kidney disease patients Benoît Tyl, A Costa, Pareen Vora et al. · European Heart Journal Oct 2024 1
8 [Retracted] Kevetrin induces apoptosis in TP53 wild‑type and mutant acute myeloid leukemia cells Roberta Napolitano, Serena De Matteis, Silvia Carloni et al. · Oncology Reports Open access 22 Jun 2026 0
9 Molecular Insights into Phytochemicals Mediated Epigenetic Regulation in Preclinical Models of Breast Cancer Pandey P, Alkhathami AG, Saeed M et al. · DOAJ (DOAJ: Directory of Open Access Journals) Open access Nov 2025 0
10 Optimal asset allocation using visual programming techniques: A quantitative analysis based on an ESG portfolio Pier Giuseppe Giribone, Damiano Verda, Francesco Mantovani et al. · International Journal of Financial Engineering 27 Jun 2025 0
11 Brilacidin: A Novel Antibiotic Designed to Prevent MRSA Joel L. Shuman, Daniel M. Jorgensen · MD Conference Express Conference paper Jun 2015 0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.